A carregar...
Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
At present, 20–30% of children with acute leukemia still relapse from current chemotherapy protocols, underscoring the unmet need for new treatment options, such as proteasome inhibition. Ixazomib (IXA) is an orally available proteasome inhibitor, with an improved safety profile compared to Bortezom...
Na minha lista:
| Publicado no: | Cells |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8002577/ https://ncbi.nlm.nih.gov/pubmed/33802801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10030665 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|